So — that pig-to-human transplant; Potential diabetes cure reaches patient; Accused MIT scientist lashes back; and morenews2021-10-23T10:00:18+00:00October 23rd, 2021|Endpoints News|
Xilio Therapeutics goes public as biopharma IPOs rumble forward in Q4news2021-10-22T14:52:39+00:00October 22nd, 2021|Endpoints News|
A new Treg player emerges with $46M and backing from Takedanews2021-10-22T14:49:43+00:00October 22nd, 2021|Endpoints News|
Oncopeptides stock craters as it pulls cancer drug Pepaxto from the marketnews2021-10-22T14:44:07+00:00October 22nd, 2021|Endpoints News|
Ocular Therapeutix hammered by a PhII failure in dry eye disease — shares tanknews2021-10-22T14:42:31+00:00October 22nd, 2021|Endpoints News|
Pfizer pitches its Covid-19 vaccine for younger children ahead of adcomm next weeknews2021-10-22T14:39:31+00:00October 22nd, 2021|Endpoints News|
No, scientists are not any closer to pig-to-human transplants than they were last weeknews2021-10-22T12:46:44+00:00October 22nd, 2021|Endpoints News|
UPDATED: Agenus calls out FDA for playing favorites with Merck, pulls cervical cancer BLA at agency’s requestnews2021-10-22T12:00:24+00:00October 22nd, 2021|Endpoints News|
Former MIT scientist David Sabatini fires back at accuser, Whitehead Institute for ‘false’ harassment allegationsnews2021-10-22T11:47:50+00:00October 22nd, 2021|Endpoints News|
Following August meltdown, Zymergen hints at salvage plans — cutting jobs and renegotiating loansnews2021-10-22T11:23:34+00:00October 22nd, 2021|Endpoints News|
